Search

Your search keyword '"Fogelman I"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Fogelman I" Remove constraint Author: "Fogelman I" Topic bone neoplasms Remove constraint Topic: bone neoplasms
41 results on '"Fogelman I"'

Search Results

1. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.

3. Beware of the focal uptake at the ischium on the bone scan in prostate cancer.

5. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate.

6. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

7. Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary.

8. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

9. Prostate cancer: role of SPECT and PET in imaging bone metastases.

10. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy.

11. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.

12. Osteoblastic bone metastases in breast cancer: is not seeing believing?

13. Positron emission tomography and bone metastases.

14. The role of nuclear medicine in monitoring treatment in skeletal malignancy.

15. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography.

16. The role of positron emission tomography in the management of bone metastases.

17. Skeletal metastases from breast cancer: imaging with nuclear medicine.

18. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.

19. Bone scanning in clinical oncology: does it have a future?

20. Detection of an elusive osteoid osteoma using a registration bone scan.

21. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

22. The bone scan: where are we now?

23. Bone scintigraphy: Part 1. Oncology and infection.

24. Selection of patients with breast cancer for routine follow-up bone scans.

25. Improved lesion detection with dimethyl-amino-diphosphonate: a report of two cases.

26. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.

27. The prognostic and therapeutic implications of the positive radionuclide bone scan in clinically early breast cancer.

28. Reappraisal of the baseline bone scan in breast cancer.

29. Osteocalcin: a potential marker of metastatic bone disease and response to treatment.

30. Bone secondaries in breast cancer: the solitary metastasis.

31. "Delta sign" in bone scan interpretation--a cautionary note.

32. Bone scan appearance of a Paget's osteosarcoma: failure to concentrate HEDP.

33. A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.P.

34. Serial scintiscanning in breast cancer: the indications and prognostic value.

35. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication.

36. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

37. Biochemical prediction of response of bone metastases to treatment.

38. A single plasma sample method to assess disease activity in patients with bone metastases from carcinoma of the prostate.

39. Diphosphonate bone scanning agents--current concepts.

40. Hypercalcaemia and metastatic bone disease: is there a causal link?

41. Bone scan flare predicts successful systemic therapy for bone metastases.

Catalog

Books, media, physical & digital resources